VERTEX PHARMACEUTICALS INC / MA

Drug pipeline (24)

Asset	Stage	Revenue	Trials	Status
ACAZICOLCEPT	phase2	—	3	completed, terminated
AVN-944	phase2	—	2	terminated, withdrawn
BAMOCAFTOR	phase3	—	6	completed, terminated
BELNACASAN	phase2	—	2	no active trials
DECERNOTINIB	phase2_3	—	6	no active trials

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (243)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT01590459	phase2	completed	2012-04-01	2014-07-01	Vertex Pharmaceuticals Incorporated	24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
NCT01052194	phase2	completed	2010-02-01	2011-07-01	Vertex Pharmaceuticals Incorporated	A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis
NCT03764072	phase2	completed	2018-12-12	2019-01-17	Vertex Pharmaceuticals Incorporated	A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy
NCT04208529	phase3	enrolling_by_invitation	2021-01-20	2039-09-30	Vertex Pharmaceuticals Incorporated	A Long-term Follow-up Study in Participants Who Received CTX001
NCT01754935	phase2	completed	2013-01-01	2014-01-01	Vertex Pharmaceuticals Incorporated	A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

FDA applications (11)

Application

Type

Applicant

Products

BLA 125787

BLA

Vertex Pharmaceuticals Inc

NDA 201917

NDA

VERTEX PHARMACEUTICALS INC

NDA 203188

NDA

VERTEX PHARMACEUTICALS INC

NDA 206038

NDA

VERTEX PHARMACEUTICALS INC

NDA 207925

NDA

VERTEX PHARMACEUTICALS INC